Get it wrong, and the consequences show up fast. Budget overruns from unplanned change orders. Coordination gaps between vendors who don't talk to each other. Or worse, a sponsor that's lost sight of what's actually happening in their own study. This article breaks down both models, compares them head-to-head, and gives you a practical framework for choosing.
TL;DR
- Full-service CRO manages end-to-end trial delivery under one accountable provider
- FSP embeds specialists within your own systems and processes, so you retain operational control
- Choose full-service when internal bandwidth is limited or the trial spans multiple countries
- Choose FSP when strong internal infrastructure is already in place and you need to scale specific functions
- Hybrid models let sponsors outsource some functions end-to-end while embedding FSP talent in others
Full-Service CRO vs. FSP: Quick Comparison
| Factor | Full-Service CRO | FSP |
|---|---|---|
| Operational Control | Provider manages execution; sponsor has less daily involvement | Sponsor retains direct oversight; staff work in sponsor systems |
| Cost Structure | Milestone-based, can include change-order costs | FTE-based, more predictable for budgeting |
| Best Fit | Multi-country, complex-protocol, resource-constrained sponsors | Sponsors with strong internal PMO capability |
| Talent Continuity | Resources often shared across multiple sponsor projects | Dedicated teams build institutional knowledge over time |
| Coordination | Single point of accountability | More sponsor-side governance needed |
What Is a Full-Service CRO?
A full-service CRO manages the entire clinical development lifecycle, from study startup and regulatory strategy through data analysis and final reporting, under one accountable structure.
According to PPD's analysis of FSP versus FSO, this arrangement is typically awarded per study or protocol. The CRO runs the work through its own systems and SOPs under a dedicated project manager.
The core benefit: consolidated delivery reduces vendor management burden. You're coordinating with one provider instead of juggling five separate contracts, which matters most when a study spans multiple regions.
The trade-off: less direct control, and potentially slower response when priorities shift mid-study.
Use Cases of Full-Service CRO
Full-service arrangements make the most sense for sponsors:
- Entering new geographies without established regulatory or operational infrastructure
- Running multi-regional trials that need centralized coordination
- Lacking the internal PMO capacity to manage multiple vendors directly
A Tufts CSDD/ICON analysis of 117 pivotal trials found that "finished on time" was the most common outcome for full-service trials, while FSP and in-house models more often finished late.
That said, full-service trials in the same pilot tended to be larger and more complex. Treat the finding as an association to weigh against your study's scope, not a clean cause-and-effect claim.
DRK Research Solutions operates this model across Europe, the Middle East, Asia, Africa, and the Americas, combining full-service CRO capabilities with CDMO services for Phase II–IV trials and generics/hybrid product development. That integrated model suits sponsors who would rather not stitch together five separate regional partners on their own.
What Is an FSP Model?
An FSP arrangement means sponsors bring in dedicated specialists—in data management, biostatistics, or clinical monitoring—who work inside the sponsor's own systems and SOPs. Unlike a full-service CRO, FSP staff typically report to an insourced sponsor project manager, not a CRO-side lead.
The core benefit: you keep strategic control and decision-making authority while accessing specialized talent without building it in-house permanently.
FSP arrangements vary. Some sponsors bring in a single function, say, biostatistics only. Others run FSP support across multiple functions and multiple studies simultaneously.
Use Cases of FSP
FSP tends to work best for sponsors that:
- Have strong internal PMO capabilities already in place
- Need to scale specific functions up or down based on enrollment volume
- Want dedicated, long-term teams that build institutional knowledge over successive studies
Commonly outsourced functions under FSP include:
- Clinical operations and monitoring
- Pharmacovigilance
- Medical writing
- Regulatory affairs
Adoption trends back this up. The Avoca Group's sponsor survey found respondents allocated 72% of outsourced spend to full-service providers and 28% to FSP, but projected that split shifting to 63%/37% within three years. Smaller sponsors projected an even split closer to 50/50—a directional signal, not a confirmed adoption rate.
Separately, the Tufts CSDD/ICON pilot found FSP was the primary model in nearly half of the 117 trials studied, and the most common choice for clinical monitoring and data management.
Full-Service CRO vs. FSP: Which Is Better for Your Study?
There's no universal answer here. The right call depends on five factors:
- Internal team bandwidth — Can your PMO actually manage multiple vendor relationships day-to-day?
- Study complexity — A single-site Phase II study has very different needs than a 15-country Phase III program.
- Number of countries involved — More geographies usually strengthen the case for centralized coordination.
- Budget predictability needs — FTE-based FSP pricing is easier to forecast than milestone-based CRO contracts.
- Desired oversight level — Some sponsors want hands-on control; others want to hand off execution entirely.
Choose full-service CRO if:
- You need consolidated accountability under one vendor
- You're entering new markets or regions
- Your internal team can't absorb the operational load
Choose FSP if:
- You already have strong internal governance
- You want to retain day-to-day control
- You need to scale specific functions up or down with enrollment
Consider a hybrid approach if neither model fits on its own. A 2024 Clinical Leader column reported that all top-10 pharma companies had already deployed FSP/FSO models, and nearly half of companies ranked 11–20 by R&D spend used a mixed model.
Hybrids typically pair full-service delivery for core trial operations with FSP support for specialized or fluctuating needs. That mix keeps accountability clear without locking the sponsor into a single rigid structure.
Real-World Considerations for Sponsors Choosing an Outsourcing Model
Two mistakes come up repeatedly. Sponsors underestimate the internal coordination burden that comes with FSP, then get surprised when governance gaps slow things down. Or they hand a study to a full-service CRO and lose visibility into what's actually happening on the ground.
Whichever model you choose, define these upfront:
- Roles and decision-making authority for every function
- Escalation paths for when something goes wrong
- Performance reporting cadence and format
Those governance basics matter even more when a study crosses borders. A 2024 systematic review of international trials found that non-harmonized regulatory approvals and sponsorship structures create real operational friction across countries. Without early planning, that friction extends timelines and inflates costs.
Most successful multi-country trials in that review used a central coordinating structure with a national coordinating center in each participating country.
For sponsors focused on underserved markets or LMIC populations, this coordination challenge multiplies. DRK Research Solutions maintains local offices in Pakistan and Nepal, along with regional leadership covering the Americas and Africa, pairing full-service CRO capabilities with localized expertise in these markets.
If you're weighing which model, or which hybrid combination, fits your study's scope and geography, talk it through with a team that has run trials across both regulated and emerging markets. DRK Research Solutions' team can help map your study's specific needs against the right outsourcing structure.
Conclusion
There's no universal winner between full-service CRO and FSP. The right choice depends on three factors:
- Your internal capability and bandwidth
- Your study's complexity and therapeutic demands
- How much day-to-day oversight you want to retain
That decision shapes timeline predictability, cost control, and data integrity. Many sponsors don't lock into one model forever, either. As portfolios grow and diversify, hybrid approaches often become the practical default.
Frequently Asked Questions
What does FSP mean in a CRO?
FSP stands for Functional Service Provider, an outsourcing model where specialized staff support defined functions, like biostatistics or monitoring, while working within the sponsor's own systems and processes.
What is the main difference between FSP and a full-service CRO?
FSP provides function-specific support with the sponsor retaining control. A full-service CRO manages the entire trial end-to-end under its own structure and systems.
Can sponsors combine FSP and full-service CRO models?
Yes. Hybrid approaches are increasingly common, using full-service delivery for core operations while layering in FSP support for targeted functional needs.
Is the FSP model suitable for smaller biotech companies?
FSP can work well for biotechs with strong scientific leadership but limited operational capacity, though it requires real internal governance to manage effectively.
How do costs compare between FSP and full-service CRO models?
FSP typically uses predictable FTE-based pricing. Full-service CRO contracts often use milestone-based pricing, which can include additional change-order costs as scope evolves.
Which model is better for multi-country clinical trials?
Full-service CROs are often preferred for multi-country trials because centralized coordination reduces operational risk across differing regulatory environments.
